Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Recurrence × niraparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 2 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Neoplasms 1 Metastatic Castration-sensitive Prostate Cancer 1

Interventions

tisagenlecleucel 2 blinatumomab 2 zanubrutinib 1 selinexor 1 revumenib 1 niraparib 1 nilotinib 1 ivosidenib 1 imetelstat 1 idecabtagene vicleucel 1 ibrutinib 1 fludarabine 1 entrectinib 1 dostarlimab 1 avapritinib 1 asciminib 1 Standard of Care 1 Paclitaxel 1 Imatinib Mesylate 1 GRN163L peptide 1 Drug Therapy 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Carboplatin 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡